News
2seventy and Bristol Myers Squibb currently share in U.S. commercialization of Abecma. Bristol Myers Squibb’s Opdualag paired with blockbuster immunotherapy Opdivo failed a clinical trial ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback